Results 91 to 100 of about 10,491 (187)

ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA

Фармакоэкономика, 2015
The purpose of the work performed was assessment of cost efficiency of Raltegravir within the schemes of antiretroviral therapy as compared to the schemes on the basis of drugs from the group of protease inhibitors with adult patients with Type 1 HIV ...
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov   +4 more
doaj   +1 more source

Raltegravir: penghambat enzim integrase HIV-1

, 2014
Raltegravir efektif digunakan sebagai bagian dari kombinasi ART baik untuk pasien treatment-naive maupun pasien treatmentexperienced; aturan pemberian raltegravir dua kali per hari (BID). Harga raltegravir lebih mahal daripada harga jenis ART lain.
Herawati, Fauna
core  

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption

, 2011
The objective of this study was to address the evolution of human immunodeficiency virus type 1 (HIV-1) mutations resistant to the integrase inhibitor raltegravir after drug interruption.
Nozza, S., F. Canducci, S. Nozza, Castagna, A., Lazzarin, A., E. Ceresola, Gianotti, N., Boeri, E., N. Gianotti, Cossarin, F., Spagnuolo, V., Barda, B., Ceresola, E., Sampaolo, M., A. Galli, M. Sampaolo, A. Castagna, Galli, A., A. Lazzarin, Canducci, F., B. Barda, V. Spagnuolo, M. Clementi, Clementi, M., F. Cossarin, E. Boeri   +25 more
core   +1 more source

A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)

, 2011
Efavirenz (EFV) causes neuropsychiatric side-effects and an unfavorable blood lipid profile. We investigated the effect of replacing EFV with raltegravir (RAL) on patient preference, daytime sleepiness, sleep quality, anxiety, and lipid ...
Patrick Schmid, Calmy, A., Enos Bernasconi, Nguyen, A., Bernard Hirschel, Alain Nguyen, Mello, A.F., Cavassini, M., Elzi, L., Nguyen, Alain, Rauch, A., Calmy, Alexandra, Cecile Delhumeau, Aurelie F. Mello, Bernasconi, Enos, Schmid, Patrick, Mello, Aurelie F, Isabelle Mercier, Andri Rauch, Delhumeau, Cecile, Hirschel, Bernard, Schmid, P., Alexandra Calmy, Rauch, Andri, Luigia Elzi, Elzi, Luigia, Mercier, I., Mercier, Isabelle, Hirschel, B., Cavassini, Matthias, Matthias Cavassini, Delhumeau, C., Bernasconi, E.   +32 more
core   +1 more source

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors

Frontiers in Microbiology, 2019
More than 10 million people worldwide are infected with the retrovirus human T-cell lymphotropic virus type 1 (HTLV-1). Infection phenotypes can range from asymptomatic to severe adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy ...
Michał S. Barski, Jordan J. Minnell, Goedele N. Maertens   +2 more
doaj   +1 more source

DOCKING OF RALTEGRAVIR TO HIV-1 INTEGRASE STRUCTURE ENSEMBLE

, 2010
Docking of the drug raltegravir to HIV-1 integrase (IN) was performed based on the established Relaxed Complex Scheme (RCS) method which accounts for the flexibility of both receptor and ligand in molecular docking.
DAWEI ZHANG, CAIYI WEI, YE MEI, ZEYU LIU
core   +1 more source

Relationship between ABCB1 rs1045642 genotype and CSF-to-plasma raltegravir ratios.

, 2013
Ratio of 4-hour post-dose CSF raltegravir concentration to selected plasma raltegravir parameters stratified by ABCB1 3435 genotype. The left half of figure represents ratios of 4-hour post-dose CSF raltegravir concentrations to 0-4 hour partial plasma ...
Danielle Richardson (496182), Husamettin Erdem (496181), Daniel H. Johnson (496179), Edward P. Acosta (157846), David W. Haas (260741), Deborah Sutherland (496180)   +5 more
core   +1 more source

The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection

Терапевтический архив, 2014
AIM. To evaluate the efficiency and safety of using raltegravir (RAL) twice daily in conjunction with a once-daily fixed dose combination of abacavir (ABC)/lamivudine (3TC) in patients with HIV infection and active tuberculosis who have not previously ...
A V Kravchenko, V N Zimina, A A Popova, M O Deulina, V G Kanestri, É S Ivanova, A A Iakovlev, V V Pokrovskiĭ   +7 more
doaj  

Raltegravir Once Daily: A Review in HIV-1 Infection

, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant ...
Emma D Deeks (4985300)
core   +1 more source

Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration

, 2017
Objectives The site of pharmacological activity of raltegravir is intracellular. Our aim was to determine the extent of raltegravir cellular penetration and whether raltegravir total plasma concentration (Ctot) predicts cellular concentration (Ccell ...
Decosterd, Laurent A., Colombo, Sara, Fayet Mello, Aurélie, Cruchon, Sandra, Guignard, Nicole, Telenti, Amalio, Franc, Claudia, Biollaz, Jérôme, Cavassini, Matthias, Buclin, Thierry   +9 more
core